tolbutamide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihyperglycaemics 2696 64-77-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tolbutamide
  • aglicid
  • arkozal
  • tolbutamid
  • tolumid
  • tolumide
  • tolbutamide sodium, sterile
  • tolbutamide sodium
  • tolbutamida
A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)
  • Molecular weight: 270.35
  • Formula: C12H18N2O3S
  • CLOGP: 2.50
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 75.27
  • ALOGS: -3.13
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.50 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.11 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 123.17 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 85 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.12 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.21 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 22, 1961 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BB03 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Sulfonylureas
ATC V04CA01 VARIOUS
DIAGNOSTIC AGENTS
OTHER DIAGNOSTIC AGENTS
Tests for diabetes
FDA EPC N0000175608 Sulfonylurea
FDA Chemical/Ingredient N0000008054 Sulfonylurea Compounds
CHEBI has role CHEBI:35526 hypoglycemic agent
MeSH PA D007004 Hypoglycemic Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Diagnostic Test for Pancreatic Islet Cell Adenoma indication
Alcoholism contraindication 7200002
Asthenia contraindication 13791008
Hepatic porphyria contraindication 55056006 DOID:3133
Hypopituitarism contraindication 74728003 DOID:9406
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007
Primary adrenocortical insufficiency contraindication 373662000
Surgical procedure contraindication 387713003
Traumatic injury contraindication 417746004
Fever greater than 100.4 Fahrenheit contraindication 426000000
Prolonged-Severe Nausea and Vomiting contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.23 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sulfonylurea receptor 1, Kir6.2 Ion channel BLOCKER Kd 5.05 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Solute carrier family 22 member 6 Transporter Ki 4.26 CHEMBL
ATP-sensitive inward rectifier potassium channel 11 Unclassified BLOCKER IC50 4.50 IUPHAR

External reference:

IDSource
4017888 VUID
N0000146241 NUI
C0040374 UMLSCUI
D00380 KEGG_DRUG
33124007 SNOMEDCT_US
4017888 VANDF
4482 MMSL
10635 RXNORM
373481003 SNOMEDCT_US
5595 MMSL
d00394 MMSL
000908 NDDF
982XCM1FOI UNII
602 INN_ID
CHEBI:27999 CHEBI
CHEMBL782 ChEMBL_ID
DB01124 DRUGBANK_ID
473-41-6 SECONDARY_CAS_RN
5505 PUBCHEM_CID
CHEMBL1200874 ChEMBL_ID
D014044 MESH_DESCRIPTOR_UI
6848 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Tolbutamide HUMAN PRESCRIPTION DRUG LABEL 1 0378-0215 TABLET 500 mg ORAL ANDA 11 sections